Evaheart

Evaheart develops and manufactures left ventricular assist systems (LVAS) for treating advanced heart failure. The company's EVAHEART2 LVAS functions as a mechanical blood pump that works parallel to the heart, taking over ventricular ejection by pumping blood into the arterial system to partially or completely replace heart function. The device features an open-vane hydrodynamic impeller with large blood flow gaps, enabling preserved aortic pulsatility, low operational rpm, low shear stress, and minimal blood trauma. This design approach helps reduce the risk of thrombosis and post-implantation strokes, which affect approximately 8% of heart failure patients with traditional LVAD implantation. The EVAHEART2 system creates a pulse necessary for maintaining organ and arterial health while minimizing bleeding complications common in other pump devices. The company's technology received approval from China's National Medical Products Administration in September 2019.

Key customers and partnerships

Penn State Health Milton S. Hershey Medical Center participated in the COMPETENCE trial to evaluate the EVAHEART2 LVAS, becoming the second hospital in the US to implant the newly designed mechanical pump. As of January 2022, the clinical trial involved 40 clinical sites and 399 patients across the country.